AngioDynamics, Inc.

AngioDynamics, Inc.(ANGO)股票分析

$12.255

+0.086 (+0.70%)收盤時

Loading chart…
最高
12.470
開盤
12.260
成交量加權均價
12.26
成交量
570.60K
市值
237.52M
最低
12.070
成交金額
7.00M
企業價值/稅息折舊攤銷前利潤(TTM)
-95.26

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.

AI 分析 of AngioDynamics, Inc. (ANGO)

買進

AngioDynamics Inc is a good buy right now due to its current price of $12.365, which is significantly below the analyst price targets of $19 to $20. The stock has shown a positive momentum with a 5-day change of +10.01%, and the RSI is at 57.536, suggesting it is neither overbought nor oversold. However, the main risk is the projected losses of $0.24 to $0.29 per share for fiscal 2027, indicating ongoing financial challenges.

分析師評級(5)

上檔空間 +57.73%
持有
1 買進
4 持有
0 賣出
目前: 12.26
最低
16.00
平均
19.33
最高
24.00

Canaccord

2026-07-15

目標價

$20

買進

H.C. Wainwright

2026-07-15

目標價

$19

買進

Freedom Broker

2026-04-06

目標價

$16

買進

Canaccord

2026-04-06

目標價

$16

買進

Canaccord

2025-07-16

目標價

$17

買進

估值指標

AngioDynamics, Inc.(ANGO)目前預期本益比為 96.15,5 年平均預期本益比為 -36.05。

預期本益比

合理
5 年均值 P/E
-36.05
目前P/E
96.15
高估
218.54
低估
-290.64

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-162.95
目前EV/EBITDA
-95.26
高估
482.07
低估
-807.98

預期股價營收比

合理
5 年均值 P/S
1.53
目前P/S
1.47
高估
2.17
低估
0.89

Alphio AI 對 ANGO 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ANGO

$10.16

情境價格

基

基準

基準 · 50%ANGO

$9.75

情境價格

悲

悲觀

悲觀 · 25%ANGO

$9.26

情境價格

持有 ANGO 的大戶

A

Armistice Capital LLC

+ 持有ANGO

-4.51%

3個月報酬率

S

Systematic Financial Management LP

+ 持有ANGO

-10.05%

3個月報酬率

事件時間軸

2026-10-21 (ET)

09:00:00

AngioDynamics Announces IRE Study Results, Patients' Survival Extended to 28 Months

2026-10-14 (ET)

07:30:00

AngioDynamics' NanoKnife System Covered by Humana's Updated Medicare Policy

2026-10-08 (ET)

16:30:00

Major Averages Decline Amid Rising Oil Prices

12:30:00

Major Averages Decline as Oil Prices Surge

09:00:00

Stock Futures Lower as Oil Prices and Treasury Yields Rise

資訊

ANGO 常見問題 —— 由 Alphio AI 解答

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AngioDynamics Inc is a good buy right now due to its current price of $12.365, which is significantly below the analyst price targets of $19 to $20. The stock has shown a positive momentum with a 5-day change of +10.01%, and the RSI is at 57.536, suggesting it is neither overbought nor oversold. However, the main risk is the projected losses of $0.24 to $0.29 per share for fiscal 2027, indicating ongoing financial challenges.

5 analysts cover ANGO: 1 rate it Buy, 4 Hold and 0 Sell. The average price target is 19.33.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易